Targeting Signal Transduction Pathways in Metastatic Breast Cancer: 
A Comprehensive Review

LEE S. ROSEN,a HELEN LOUISE ASHURST,b LINNEA CHAPa

aPremiere Oncology, Santa Monica, California, USA; bACUMED, Tytherington, UK

Key Words. Human epidermal growth factor receptor • Metastatic breast cancer • Signaling pathways • Vascular endothelial growth factor • Tyrosine kinase inhibitors

Disclosures: Lee S. Rosen: None; Linnea Chap: None; Louise Ashurst: None.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors or independent peer reviewers.

ABSTRACT
Greater understanding of the underlying etiology and biology of breast cancer is enabling the clinical development of targeted therapies for metastatic breast cancer (MBC). Following the successful introduction of trastuzumab, the first human epidermal growth factor receptor (HER) biologically targeted therapy to become widely used in MBC patients, other agents have been developed. Novel agents include monoclonal antibodies such as pertuzumab, which bind to receptors on the cell surface, and tyrosine kinase inhibitors (TKIs) such as lapatinib, which target intracellular pathways such as that of the epidermal growth factor receptor. There is also growing clinical experience with antiangiogenic agents, particularly in combination with chemotherapy. These include the monoclonal antibody bevacizumab, which targets vascular endothelial growth factor receptor, and multitargeted TKIs with antiangiogenic and antiproliferative activities, such as sunitinib. Combination treatment with multiple agents targeting both the HER family and angiogenic pathways (e.g., trastuzumab plus bevacizumab) is also showing activity in the clinical setting. Despite recent advances, there are unanswered questions regarding the management of MBC with targeted agents. Future studies are necessary to determine the optimal combinations, doses, and schedules required to maximize clinical activity while minimizing toxicity. Despite the temptation to use a targeted agent in all patients, identification of patient subgroups most likely to benefit must be a key goal and will be critical to the successful future use of these treatments. The aim of this review is to summarize some of the key signaling pathways involved in tumor progression and some of the novel therapies that are in development for MBC.

The Oncologist 2010;15:216–235

INTRODUCTION
The mechanisms underlying the development of breast cancer are complex and vary among individual tumors [1]. These include genetic and epigenetic alterations, and resulting changes in the activity of signaling pathways.

Mutations or epigenetic functional inactivation of tumor suppressor genes may contribute to the early development of some tumors, and alterations in proto-oncogenes may also be involved [2]. Altered patterns of gene expression are associated with corresponding variations in growth rates.
and cellular composition [3]. Analyzing these patterns of gene expression can help to define tumor subtypes. Two of the subtypes so far identified are those with gene expression characteristics typical of basal epithelial cells (which are predominantly estrogen receptor [ER]−) and those with gene expression characteristics typical of luminal epithelial cells (which are predominantly ER+) [3, 4]. Different patterns of gene expression are also associated with differing prognoses, and genetic assay techniques are increasingly being used to provide information on outcome, including the risk for tumor recurrence and whether an individual is likely to benefit from a particular chemotherapy [5]. Typically, tumors of the ER−, basal subtype are associated with shorter relapse-free and overall survival times than those of the ER+, luminal subtype [4]. Altered patterns of gene expression can also influence the activity of specific signaling pathways. Variations in the pathways associated with the human epidermal growth factor receptor (HER) family, which are encoded by genes on different chromosomes and regulate normal breast growth and development, appear to be particularly important, not only in tumor development but also in treatment efficacy [6, 7]. Given the complex and varied factors that influence the development of breast cancer, and the use of increasingly sophisticated genetic analysis techniques, it is likely that more refined tumor subtypes and their associated prognoses will be identified [1, 8].

Current treatment strategies for metastatic breast cancer (MBC) depend upon patient and tumor classification; menopausal status, hormone receptor status, and HER-2 status may all be considered, as may site of metastatic disease (bone or soft tissue). The choice of treatment in metastatic disease is still a matter of debate, but usually involves systemic endocrine therapy or cytotoxic chemotherapy, with an anti–HER-2 agent when appropriate. Novel agents are needed because many of the current therapies have limitations. These include drug resistance, lack of target receptor expression in tumors (e.g., only 25% of breast cancer tumors have HER-2 expression), and relatively small improvements in survival [9–12]. In addition, as more treatment options become available in the first-line and adjuvant settings, there is less clarity about choices for patients with metastatic or refractory disease. Advances in the understanding of the etiology and biology of breast cancer have identified key targets among the multiple signaling pathways involved in the development, growth, and survival of breast cancer cells (Fig. 1). As such, targeted therapies are among the most promising new agents for the treatment of breast cancer.

This review focuses on some of the mechanisms and pathways influencing tumor cell proliferation, survival, and invasiveness that are being exploited to develop novel therapies for the treatment of MBC. Targets currently identified...
include HER family members and members of the mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K), and apoptotic signaling pathways. Factors modulating angiogenesis are additional targets for therapy, and recent clinical developments with antiangiogenic therapies are also reviewed. There appears to be extensive crosstalk between the pathways driving tumorigenic processes, and this provides a good rationale for inhibiting multiple pathways and processes with multitargeted agents, either as single agents or in combination.

**The HER Family**

The HER family consists of four closely related tyrosine kinase receptors: HER-1 (also termed epidermal growth factor receptor [EGFR] or ErbB-1), HER-2 (also termed ErbB-2 or HER-2/neu), HER-3 (ErbB-3), and HER-4 (ErbB-4) [13]. Through their interconnected cellular signaling network, the HER family regulates diverse biological processes, including cell proliferation, differentiation, and survival [13, 14], and plays a key role in the development and progression of breast cancer [13, 15, 16]. Expression of HER family members in breast cancer tumors has a significant impact on tumor aggressiveness and patient survival. HER-1 and HER-2 are expressed in approximately 16%–48% and 25%–30% of breast cancer tumors, respectively, and their expression correlates with a more aggressive disease course, shorter survival time, and higher risk for resistance to endocrine therapies [9, 10, 17–23]. HER-3 expression, observed in approximately 18% of tumors, also correlates with shorter overall survival [19]. Interestingly, expression of HER-4 (found in approximately 12% of tumors) has been associated with more favorable tumor characteristics and longer survival [18, 19].

Each HER receptor has an extracellular domain involved in ligand binding, a helical transmembrane segment, and an intracellular protein tyrosine kinase domain [13, 24].
(Fig. 2). On ligand binding, the extracellular domains of the receptors undergo conformational changes, which allows them to form homodimers (consisting of two identical receptors) or heterodimers (consisting of two different receptors) of the HER family [13, 24] (Fig. 2). More than 10 ligands have so far been identified that bind to HER-1, HER-3, and HER-4, including epidermal growth factor (EGF), transforming growth factor α, amphiregulin, beta-cellulin, epiregulin, heparin-binding EGF, and neuregulin 1 through neuregulin 4 [13]. Putative ligands of HER-2 have been characterized, but no specific ligand has yet been identified [24]. This has clinical implications in terms of there being no alternative approach to blocking this pathway, and this may be related to the development of resistance to HER-2 blockade.

The specific receptors involved in each dimer affect the type and number of downstream effectors activated, and also influence the downstream regulation mechanism for the ligand-bound receptors [24]. Dimerization of HER receptors induces phosphorylation of their intracellular tyrosine kinase domains, which provide docking sites for adaptor proteins and signaling enzymes [24]. These molecules act as a link between membrane receptor kinases and “downstream” intracellular protein kinases, which results in the activation of multiple signaling pathways, of which the MAPK and PI3K pathways are probably the best understood [24] (Fig. 2). Given the absence of known ligands for HER-2, and lack of tyrosine kinase activity of HER-3, it is assumed that these receptors must form heterodimers with another member of the HER family in order to activate signaling [24]. HER-2 is the preferred dimerization and signaling partner for all other members of the HER family, and it appears to function mainly as a coreceptor, increasing the affinity of ligand binding to dimerized receptor complexes [24, 25]. With their multiple ligands, many dimerization combinations, and large number of downstream effectors, the HER family mediates an extensive range of signals, controlling a variety of cellular processes, including cellular proliferation, apoptosis, and angiogenesis [24, 26] (Fig. 2).

Targeted Therapies Directed at the HER Family of Receptors
Numerous agents targeting individual members of the HER family have been developed for use in the treatment of breast cancer. Table 1 summarizes those that are licensed or in phase III clinical development. Existing therapeutic approaches have largely focused on two classes of agents. The first comprises monoclonal antibodies that bind to extracellular regions of HER to interfere with receptor function (e.g., trastuzumab, pertuzumab, and a number of pan-HER inhibitors). Trastuzumab binds to the juxtamembrane region of HER-2 with high specificity, but it is not currently known how it specifically interferes with HER-2 function [27]. Pertuzumab is the first in a class of HER-2 dimerization inhibitors. Binding to HER-2 inhibits its dimerization with other HER receptors and this is thought to result in slowed tumor growth [28]. The second class of HER-targeted agents comprises the small molecule tyrosine kinase inhibitors (TKIs) that inhibit enzyme function of HER family members intracellularly. Oral TKIs include lapatinib, neratinib (both inhibit HER-1 and HER-2), erlotinib and gefitinib that target the intracellular domain of HER-1, and the irreversible pan-HER inhibitors PF-00299804 and canertinib, which inhibit the kinase signaling of multiple HER family members [29, 30].

Extracellular Targeted Therapies:
Monoclonal Antibodies

Trastuzumab. Trastuzumab, administered as an i.v. infusion, is approved in the U.S. and Europe for the treatment of HER-2–overexpressing MBC [31]. It is standard-of-care treatment for MBC patients with HER-2–overexpressing tumors, both as first-line treatment in combination with chemotherapy and as a single agent in women who have HER-2–overexpressing MBC that has progressed after chemotherapy for metastatic disease [32, 33]. Trastuzumab is approved for the adjuvant treatment of HER-2+ node-negative (ER-/progesterone receptor [PgR]− or with one high-risk feature) or node-positive breast cancer, either in combination with chemotherapy or as a single agent following multimodality anthracycline-based treatment.

Studies have evaluated a range of different trastuzumab-based combination regimens for the first-line treatment of MBC (Table 2A) [34–48]. Additionally, a number of trials are ongoing investigating trastuzumab in combination with hormonal therapy in MBC patients [49, 50].

When administered as a single agent, trastuzumab has documented efficacy as a first-line therapy, with response rates typically in the range of 23%–33% [51–53]. However, no benefit has been observed treating patients with single-agent trastuzumab followed by chemotherapy with or without trastuzumab on progression [35, 41]. Of those patients with MBC who do achieve an initial response, many experience disease progression within 12 months as a result of the high proportion of HER-2–overexpressing tumors that have intrinsic resistance to this agent [54]. However, changing the traditional treatment paradigm in patients progressing on trastuzumab and administering further trastuzumab-based therapy beyond disease progression may have clinical benefit [55, 56]. This “treatment beyond progres-
A "trastuzumab plus chemotherapy" approach is increasingly being studied in clinical trials by combining trastuzumab either with chemotherapy or with another targeted agent, such as the TKI lapatinib and the HER-2 dimerization inhibitor pertuzumab (Table 2B).

A phase III evaluation of continuing trastuzumab and capecitabine versus capecitabine alone in patients \((n = 156)\) with HER-2\(^+\) MBC who had progressed during trastuzumab treatment found that the combination led to a longer time to progression (TTP), by nearly 3 months, than with capecitabine alone \((8.2 \text{ months versus } 5.6 \text{ months}; p = .034)\) [43]. In addition, recent phase II data showed how 50% of patients who had progressed on trastuzumab therapy benefited from combination treatment with pertuzumab and trastuzumab; combination treatment resulted in an overall response rate (ORR) of 24.2% (complete response rate, 7.6%; partial response [PR] rate, 16.7%; rate of stable disease [SD] \(>6 \text{ months, } 25.8\%\)) and a progression-free survival (PFS) duration of 24 weeks [28, 45]. The combination appeared to be well tolerated, and no patients were withdrawn as a result of toxicities. A phase III clinical trial (CLEOPATRA) evaluating trastuzumab plus chemotherapy with and without pertuzumab for the first-line treatment of HER-2\(^+\) MBC is currently ongoing [45]. Interestingly, an evaluation of trastuzumab use beyond disease progression by the National Comprehensive Cancer Network found that, of the total 165 patient cohort, 46 patients stopped first-line treatment because of disease progression. Of those 46 patients, 74% continued to receive trastuzumab as part of second-line therapy and nine of 46 (19.6%) patients were treated in a clinical trial [48].

Trastuzumab-DM1 (T-DM1) is an anti–HER-2 antibody drug conjugate comprising trastuzumab linked to the maytansine derivative DM1. Combining these two agents facilitates anti–HER-2 activity as well as targeted intracellular delivery of a potent cytotoxic agent. Single-agent T-
### Table 2. Summary of key phase II and III trials of: (A) trastuzumab in combination with chemotherapy (first-line treatment) and (B) trastuzumab treatment beyond progression

| Trial | Phase | Patient characteristics | Treatment regimen | Primary endpoint | ORR | PFS/TTP | OS | Safety |
|-------|-------|-------------------------|-------------------|-----------------|-----|---------|----|--------|
| **A. Trastuzumab + chemotherapy** | | | | | | | | |
| [34] | II | HER-2+ (n = 186) | D alone versus D + T | ORR | ORR, 34% (D) versus 61% (D + T) (p = .0002) | Median TTP, 6.1 mos (D) versus 11.7 mos (D + T) (p = .0001) | Median OS, 22.7 mos (D) versus 31.2 mos (D + T) (p = .0325) | Combination treatment produced little additional toxicity |
| **HERTAX [35]** | II | HER-2+ (n = 99) | Sequential T + D versus combination T + D | PFS | ORR, 50% with sequential treatment versus 73% with combination (p = .02) | Median PFS, 10.8 mos (sequential) versus 9.4 mos (combination); HR, 1.21 (combination); HR, 1.45 (p = .42) | Median OS, 20.2 mos versus 30.5 mos; HR, 1.45 (p = .15) | More grade 3 or 4 toxicity with combination treatment |
| [36] | II | HER-2+ (n = 30) | T + nab-paclitaxel + C | ORR | ORR, 53%; CR, 2 (7%); PR, 14 (47%) | Median TTP, 15.9 mos (95% CI, 7.3–28.0); median DR, 28 mos | Not available | Well tolerated |
| [37] | II | HER-2+ (n = 30) | PEG liposomal doxorubicin + T | ORR | CR/PR, 52% | Median PFS, 12 mos | Not available | Cardiotoxicity (asymptomatic decreases in LVEF) |
| [33] | III | HER-2+ (n = 469) | Standard chemotherapy alone versus standard chemotherapy + T | TTP | ORR, 32% versus 50% (+T) (p < .001) | Median TTP, 4.6 mos versus 7.4 mos (+T) (p < .001) | Median OS, 20.3 mos versus 25.1 mos (+T) (p = .046) | Most important AE, cardiotoxicity |
| **TRAVIOTA [38]** | III | HER-2+ (n = 81) | T + V versus T + PX/D | ORR | ORR, 51% (T + V) versus 40% (T + PX/D) (p = .37) | Median TTP, 8.5 mos (T + V) and 6.0 mos (T + PX/D) (p = .39) | Not available | Comparable safety profiles |
| [39] | III | HER-2+ (n = 196) | C + T + PX versus T + PX | ORR | ORR, 52% (C + T + PX) versus 36% (T + PX) (p = .04) | Median PFS, 10.7 mos (C + T + PX) versus 7.1 mos (T + PX) (p = .03) | Not available | More grade 4 neutropenia with carboplatin regimen |
| [40] | III | HER-2+ (n = 263) | C + T + D versus T + D | ORR | ORR, 73% in both arms | Median TTP, 10.4 mos (C + T + D) versus 11.1 mos (T + D) (p = .57) | Not available | Effective and well tolerated; no significant cardiotoxicity |
| [41] | III | HER-2+ (n = 105) | Combination T + D versus sequential T → T + D | PFS and OS | ORR, 68% (combination T + D) versus 15% (sequential T alone) versus 47% (sequential T alone) versus 12.4 mos (sequential T + D); significant difference for combination versus sequential T + D | PFS, 14.6 mos (combination T + D) versus 3.7 mos (sequential T alone) versus 12.4 mos (sequential T + D); significant difference for combination versus sequential T + D | OS, significant difference for combination versus sequential T + D | No difference in LVEF; comparable safety profile |

(continued)
| Trial | Phase | Patient characteristics | Treatment regimen | Primary endpoint | ORR | PFS/TTP | OS | Safety |
|-------|-------|------------------------|-------------------|------------------|-----|---------|----|--------|
| CHAT [42] | III | HER-2^+ (n = 222) | X + T + D versus T + D | ORR | ORR, 71% (X + T + D) versus 73% (T + D) (p = .717) | Median TTP, 18.2 mos (X + T + D) versus 13.8 mos (T + D) (p = .045) | OS, not mature at yr 1 and yr 2; survival higher with X + T + D | No greater cardiotoxicity with triple combination |

B. Trastuzumab treatment beyond progression

| [43] | III | HER-2^+ (n = 156) | Continuing T + X versus X | ORR | ORR, 48% (T + X) versus 27% (X) (p = .0115); CBR, 75% (T + X) versus 54% (X) (p = .007) | Median TTP, 8.2 mos (T + X) versus 5.6 mos (X) (p = .0338) | Median OS, 25.5 mos (T + X) versus 20.4 mos (X) (p = .257) | Similar toxicity for T + X versus X alone |

| [44] | II | HER-2^+ (n = 31) | TP + T | ORR | ORR; PR, 7 patients (26%), SD 4 mos, 5 patients (19%); CBR, 17 patients (63%) | Not available | Not available | Well tolerated |

| [28, 45] | II | HER-2^+ (n = 66) | T + PZ | ORR | ORR, 24% (CR, 5 patients; PR, 11 patients); SD >6 mos, 17 patients; CBR, 50%; DR, 25 wks | Not available | Not available | Well tolerated |

| [46] | I | HER-2^+ (n = 27) | R + T + PX | ORR | CR, 5%; PR, 36%; SD, 50%; DCR (PR/SD >6 wks), 77%; In 11 patients with taxane and T-resistant tumors: CR, 11%; PR, 56%; SD, 33%; DCR, 100% | Not available | Not available | Well tolerated (very low incidence and severity of AEs) |

| [47] | I | HER-2^+ (n = 37) | R + T + V, 5 mg daily (n = 17) versus weekly 20 mg/day (n = 6) versus weekly 30 mg/day (n = 14) | ORR | Of 34 patients: 5 mg daily: CR, 1; PR, 2; SD, 9; weekly 20 mg/day: PR, 1; SD, 3; weekly 30 mg/day: PR, 2; SD, 9; CBR, 50% | Not available | Not available | Generally well tolerated |

| [48] | NA | HER-2^+ | T (retrospective analysis) | Not available | 74% (46 of 62 patients) continued to receive T as part of second-line treatment following PD | Not available | Not available | Not available |

Abbreviations: AE, adverse event; C, carboplatin; CBR, clinical benefit rate; CI, confidence interval; CR, complete response; D, docetaxel; DCR, disease control rate; DR, duration of response; HER, human epidermal growth factor receptor; HR, hazard ratio; L, lapatinib; LVEF, left ventricular ejection fraction; NA, not applicable; NCCN, National Comprehensive Cancer Network; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; PX, paclitaxel; PZ, pertuzumab; R, RAD001; SD, stable disease; T, trastuzumab; TP, tanespimycin; TTP, time to progression; V, vinorelbine; X, capecitabine.
DM1 was well tolerated and active (ORR, 25%; clinical benefit rate [CBR], 34.8%) and no dose-limiting cardiotoxicity was observed in a phase II study of 112 patients with pretreated MBC [62].

Limitations of Trastuzumab Therapy. Trastuzumab is unable to penetrate the blood–brain barrier [63], and overexpression of HER-2 is known to be associated with a greater risk for central nervous system (CNS) metastases [64]. Patients with HER-2+ MBC treated with trastuzumab appear to be at greater risk for developing CNS metastases than those who do not receive trastuzumab therapy [65, 66]. However, HER-2+ patients with CNS metastases who are treated with trastuzumab appear to have a longer overall survival duration than those who are HER-2− or those unselected for HER-2 status. This may reflect greater control of extracranial disease as a result of trastuzumab therapy [67].

Treatment with trastuzumab is associated with a higher risk for cardiomyopathy (left ventricular dysfunction and congestive heart failure), particularly when used in combination with paclitaxel or anthracyclines [68]. However, these cardiotoxic effects appear to be reversible once trastuzumab treatment is discontinued or if they are managed with appropriate medical therapy [69, 70]. The cellular mechanisms contributing to the cardiotoxicity observed with trastuzumab are still being explored. It is known that HER-2 plays an important role in cardiomyocyte development and function, and trastuzumab-induced inhibition of HER-2 signaling in cardiomyocytes may be a central mechanism underlying the observed cardiomyopathy [71]. However, the full explanation is likely to be more complex. Cardiotoxicity does not appear to be an issue with the TKI lapatinib, which inhibits both HER-1 and HER-2 [71]. Although cardiotoxicity is the primary safety concern with trastuzumab, potentially severe hypersensitivity reactions to infusion have also been reported [31].

In summary, trastuzumab is an effective treatment for patients with HER-2+ disease, although its use is limited to this group (approximately 25%) [20]; accurate patient selection for treatment is important, using an appropriate method, such as immunohistochemistry or fluorescence in situ hybridization, to detect HER-2 overexpression. Additionally, not all HER-2+ patients respond to treatment with trastuzumab, and the development of resistance is an issue. In the future, it may be possible to overcome resistance by combining trastuzumab with new therapies such as pertuzumab, by switching to an agent such as lapatinib that inhibits both HER-1 and HER-2 activity, or, if proven effective, the use of one of the pan-HER inhibitors currently in development. The efficacy that trastuzumab has demonstrated in the metastatic setting has provided the rationale for several studies investigating the use of trastuzumab plus chemotherapy as adjuvant treatment for patients with early-stage HER-2+ breast cancer, a key area for development [72–77]. Cardiotoxicity remains a key safety concern for the use of trastuzumab, although in most patients this is reversible once trastuzumab is discontinued and/or appropriate medical treatment is given [68–70].

Intracellular Targeted Therapies: TKIs

Lapatinib. Lapatinib is approved in the U.S. (March 2007) and European Union (EU) (June 2008) for use (oral administration) in combination with capecitabine for the treatment of patients with advanced breast cancer or MBC whose tumors overexpress HER-2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab [78, 79].

In a pivotal phase III study that provided the basis for regulatory approval, a combination of lapatinib plus capecitabine led to a significantly longer median TTP than with capecitabine alone (8.4 months versus 4.4 months; \( p < .001 \)) in patients with progressive, HER-2+, locally advanced or MBC refractory to trastuzumab \( (n = 324) \) [80]. This was a notable finding, in that 97% of the patients had previously received treatment with trastuzumab and given that the data were similar to those reported in the phase III trastuzumab plus capecitabine trial in patients progressing on trastuzumab (TTP, 8.4 months versus 8.2 months) [43]. The incidences of adverse events (including those leading to treatment discontinuation) and symptomatic cardiac events were similar in both treatment groups [80].

Additional studies are ongoing to evaluate lapatinib in combination with trastuzumab, other chemotherapy agents, hormonal therapy, anti–vascular endothelial growth factor receptor (VEGF) agents, and as adjuvant therapy [59, 81, 82]. A recent phase III trial (EGF104900) showed a significantly longer PFS time with the combination of lapatinib and trastuzumab than with lapatinib alone (12 weeks versus 8.1 weeks; \( p = .008; \) hazard ratio [HR], 0.73) in patients with heavily pretreated, HER-2+ MBC progressing on trastuzumab [59]. A summary of key lapatinib combination trials is presented in Table 3 [59, 80, 82–84].

Contrary to trastuzumab, lapatinib has activity against CNS metastases in patients with HER-2+ breast cancer [85–87]. These data suggest that, as a small molecule TKI, it may be able to cross the blood–brain barrier to provide effective therapeutic concentrations in cerebrospinal fluid (unlike monoclonal antibodies such as trastuzumab).

Lapatinib appears to be associated with less cardiotoxicity than trastuzumab. An analysis of 3,689 patients treated with lapatinib in clinical trials reported a 1.6% incidence of cardiac events, with most events being asymptomatic and

www.TheOncologist.com
Table 3. Summary of key lapatinib combination trials

| Trial        | Phase | Patient characteristics | Treatment regimen | Primary endpoint | ORR | PFS/TTP                  | Safety                                                                 |
|--------------|-------|--------------------------|-------------------|------------------|-----|--------------------------|------------------------------------------------------------------------|
| [80]         | III   | HER-2\(^+\), locally advanced breast cancer or MBC refractory to trastuzumab (n = 324) | L + X versus X | TTP              | 22% (L + X) versus 14% (X) (p = .09) | Median TTP, 8.4 mos (L + X) versus 4.4 mos (X) (p < .001) | Adverse events and cardiac events similar in both groups |
| EGF1049000   | III   | Heavily pretreated MBC (n = 296) | L + T versus L | PFS              | 10.3% (L + T) versus 6.9% (L) (p = .46) | Median PFS, 12.0 wks (L + T) versus 8.1 wks (L) (p = .008; HR, 0.73; 27% lower risk for progression) | Manageable toxicity                                                                 |
| VEG20007     | II    | HER-2\(^+\) MBC; cohort 1 (C1): P, 400 mg/day + L, 1,000 mg/day or L, 1,500 mg/day (n = 140); C2: P, 800 mg/day + L, 1,500 mg/day or L, 1,500 mg/day (n = 40) | L + PZ versus L | RR               | C1: 12-wk RR, 36% (L + PZ) versus 22% (L); PD, no significant difference. C2: TBD | C1: 12-wk PFS, 84.1% (L + PZ) versus 63.2% (L) (p = .009) | Manageable toxicity; C1: diarrhea, rash, and nausea; C2: diarrhea, nausea, fatigue, hypertension, and rash |
| [84]         | II    | HER-2\(^+\) advanced breast cancer or MBC (n = 52) | L + B             | PFS              | 13%; PR, 7; CBR (CR + PR + SD ≥24 wks), 31% | 12-wk PFS, 69% | Generally well tolerated; asymptomatic LVEF decline, n = 2; grade 2; LVEF dysfunction, n = 3, one grade 2 and one grade 1 |

Abbreviations: B, bevacizumab; CBR, clinical benefit rate; CR, complete response; G, grade; HER, human epidermal growth factor receptor; HR, hazard ratio; L, lapatinib; LVEF, left ventricular ejection fraction; MBC, metastatic breast cancer; ORR, objective response rate; PD, progressive disease; PFS, progression-free survival; PR, partial response; PZ, pazopanib; RR, response rate; SD, stable disease; T, trastuzumab; TBD, to be determined; TTP, time to progression; X, capecitabine.

reversible/nonprogressive [88]. A recent analysis from the Lapatinib Expanded Access Program, in which lapatinib was given in combination with capecitabine to 2,500 patients with advanced breast cancer, reported a 0.6% incidence of decreased left ventricular ejection fraction [89]. However, as lapatinib development is extended to include the treatment of patients with lower-risk primary breast cancer, it will be increasingly important to monitor cardiotoxic effects. The most common adverse effects associated with lapatinib treatment are gastrointestinal; lapatinib-related diarrhea generally occurs early in the course of treatment, is mild to moderate, and does not require treatment, although monitoring is important to identify patients who may need intervention [90].

**Erlotinib and Gefitinib.** In the U.S. and Europe, erlotinib monotherapy is currently approved for the treatment of patients with previously treated, locally advanced or metastatic non-small cell lung cancer (NSCLC) or locally advanced (U.S. only), unresectable (U.S. only) or metastatic pancreatic cancer [91]. Gefitinib monotherapy is currently approved in the U.S. for the continued treatment of NSCLC in patients who are benefiting or have benefited from treatment with gefitinib after failure of both platinum-based and docetaxel chemotherapies [92]; it has also now been approved in Europe for use in NSCLC patients with **EGFR** mutations, in all lines of therapy. Recent clinical studies have not demonstrated any significant clinical benefit for erlotinib or gefitinib either as single agents or in combination with other agents in MBC [93–99]. Given their lack of activity as monotherapy in MBC, studies continue to investigate the efficacy of erlotinib and gefitinib in combination with other targeted therapies, chemotherapy, or hormonal agents; however, tolerability issues may limit this approach.

**Neratinib.** Neratinib (HKI-272) is an orally administered, irreversible, pan-erbB kinase inhibitor [100]. The observation that some patients with chronic myelogenous leukemia were developing resistance to the TKI imatinib led to the development of neratinib. In preclinical models, neratinib has been shown to have promising antiproliferative activity in both HER-2–dependent cell lines and tumor xenografts. Clinical development has seen trials conducted in patients with NSCLC and in patients with breast cancer. In a phase I dose-escalation study in patients with solid tumors, the maximum-tolerated dose was determined to be 320 mg/day and the 240-mg/day dose was chosen for use in phase II studies. A total of 25 patients in that study had MBC. Of these, eight (32%) had a PR and one experienced SD for >24 weeks. Importantly, all responders were heavily pre-treated, having received prior trastuzumab, anthracycline,
and taxane therapy [101]. Phase I/II data have confirmed that neratinib has antitumor activity in patients with HER-2+ MBC, either as a single agent in trastuzumab-refractory patients or in combination with trastuzumab, and the safety profile of this agent has been manageable [102, 103]. Phase III trials that are ongoing include a study of single-agent neratinib in trastuzumab-pretreated patients with early breast cancer, a study of neratinib versus lapatinib and capecitabine in trastuzumab-pretreated MBC patients, and a study of neratinib plus paclitaxel versus trastuzumab plus paclitaxel as first-line therapy for patients with MBC [104].

In summary, experience with agents targeting the HER family shows that agents such as trastuzumab, lapatinib, and neratinib are clinically active in MBC and are generally well tolerated. However, evidence is increasing that agents targeting HER-1 alone are not associated with clinical benefit in the MBC setting. Accurate patient selection based on HER-2 overexpression is essential for trastuzumab-based treatment and is likely to be important for other agents in this class. However, identifying suitable patients may prove more difficult for TKIs, because receptor overexpression alone does not seem to predict response to treatment [13].

HER-targeted agents may need to be used in combination with chemotherapy to provide clinically relevant activity, according to classical ORR criteria. Targeting HER-2 is associated with cardiac toxicity, which is an especially important consideration in the adjuvant setting and when combining anti–HER-2 agents with cardiotoxic chemotherapeutic drugs. Targeting HER-1 in combination with HER-2, as with the TKIs lapatinib and neratinib, appears to reduce the risk for cardiotoxicity, although the exact mechanisms underlying this observation remain unclear.

TARGETING DOWNSTREAM EFFECTOR MOLECULES

Targeting HER receptors with extracellular monoclonal antibodies and intracellular TKIs has shown promising clinical activity. There is, however, a need for better treatment of MBC patients because many of these current therapies are restricted to a subset of the MBC patient population. Targeting cellular signaling pathways, such as the MAPK and PI3K pathways, downstream of HER receptors may be an attractive avenue for novel treatments. Additionally, there is some evidence that targeting heat shock proteins (Hsps) and the apoptotic pathway may be viable options for future therapeutic strategies in MBC. Recent developments in this field are briefly discussed in the following sections.

MAPK and PI3K Signaling Pathway Overview

The MAPK pathway, also termed the extracellular signal-regulated kinase (ERK) pathway, contains downstream effectors of the HER family and other tyrosine kinases, and is a central part of the signaling networks that control fundamental cellular processes, including cell proliferation, differentiation, and survival [105] (Fig. 1). The PI3K pathway also plays a central role in numerous cellular signaling pathways, and has been linked to a range of processes involved in tumor development, including cell proliferation, cell growth, cell motility, cell survival, and angiogenesis [24] (Fig. 1).

Targeted Therapies Directed at the MAPK and PI3K Signaling Pathways

The farnesyl transferase inhibitor tipifarnib (R115777) was evaluated in phase III trials for the treatment of breast cancer, although further development has now been terminated [106–108]. AZD6244 (ARRY-142886), an inhibitor of the enzyme MEK, a component of the MAPK pathway, is currently in phase I clinical studies in several cancer types, including breast cancer. Therapies targeting the PI3K pathway include perifosine (KRX-0401), which inhibits Akt phosphorylation [109], and the rapamycin analogs that target mammalian target of rapamycin, such as temsirolimus (CCI-779) [110–112] and everolimus (RAD001) [46, 47, 113, 114]. Recent data from two phase I trials suggest that everolimus can help overcome resistance to trastuzumab in women with HER-2+ MBC. Everolimus plus trastuzumab and weekly paclitaxel was shown to slow tumor growth in 77% of patients, and the combination of everolimus with trastuzumab and vinorelbine halved tumor growth in 62% of patients [46, 47]. Although early indications suggest that targeting components of the PI3K pathway may have some activity in the treatment of MBC, additional data, including an understanding of combinations and patient selection, are required.

Apoptosis Signaling Pathway Overview

Apoptosis, the process of programmed cell death, is governed by complex, gene-directed pathways [115–117]. Dysregulation of apoptosis plays a key role in tumorigenesis and can allow tumor cells to become resistant to anticancer treatments [116, 117]. Rationale for targeting apoptosis in the treatment of breast cancer includes the overexpression of the Bcl-2 protein in 40%–80% of human breast tumors, which is associated with both resistance to chemotherapy [118] and a better prognosis after chemotherapy [119]. Additionally, the association of Bcl-2 with ER and/or PgR, loss of expression of the gene for the pro-apoptotic protein Bax, and differential expression of tumor necrosis factor–related apoptosis-inducing ligand-receptor 2 have all been correlated with prognosis in breast cancer patients [118–121].
**Targeted Therapies Directed at the Apoptotic Pathway**

Anticancer agents targeting the components of apoptotic pathways are in the early stages of development, and no agent specifically targeting apoptosis has yet been approved for use in cancer treatment. A range of approaches is being tested, including antisense DNA oligonucleotides and antibody and small molecule inhibitors of the components of apoptotic pathways. Few clinical data are currently available in breast cancer; however, preclinical studies show that such agents do have anticancer activity, suggesting that this may be a promising approach, particularly when used in combination with chemotherapy.

**Hsp Signaling Pathway Overview**

Hsp-90 acts as a regulator of the HER family by functioning as a chaperone protein, binding to and maintaining client molecules in their active conformation [122]. Hsp-90 is overexpressed two- to tenfold in human tumor cells [122]. Although Hsp-90 is associated with many cellular pathways and effectors, both HER-1 and HER-2 require chaperoning by Hsp-90 for their stability [122], and Hsp-90 is able to disrupt the ability of HER-2 to form signaling heterodimers on ligand binding [123].

**Targeted Therapies Directed at the Hsp-90 Apoptotic Pathway**

A range of Hsp-90 inhibitors has been developed and evaluated in clinical trials for the treatment of breast cancer, including tanespimycin (KOS-953, 17-AAG in Cremophor). Recent data from a phase II study of tanespimycin in combination with trastuzumab as second-line therapy in patients with HER-2+ MBC showed evidence of good antitumor activity (CBR [PR + SD ≥4 months], 63%), and the combination was very well tolerated [44]. Further studies are needed to confirm the effectiveness and safety profile of current Hsp-90 inhibitors.

**Targeting the Angiogenesis Pathway**

The process of angiogenesis (the formation of new blood vessels from a pre-existing vascular bed) is complex and dynamic, and it is regulated by a range of pro- and antiangiogenic molecules [124]. The VEGF and platelet-derived growth factor (PDGF) families of proteins and their receptors (VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, and PDGFR-β) appear central to the process [124]. Activation of VEGFRs and PDGFRs initiates signaling that results in numerous cellular responses, including survival, mitogenesis, migration, proliferation, and differentiation [124, 125]. Activation of the VEGF pathway also increases vascular permeability and the movement of endothelial progenitor cells from the bone marrow into the peripheral circulation [124].

Primary breast tumors express a variety of different angiogenic factors, with VEGF being the most abundant. High VEGF expression appears to be correlated with poor prognosis and response [126]. Levels of VEGF in breast cancer tumors are a prognostic factor for relapse-free and overall survival in patients with both lymph node–negative and lymph node–positive disease [127, 128], and they predict response to both tamoxifen and chemotherapy in advanced disease [129]. Similarly, a proportion of invasive breast cancers that overexpress PDGFR-α have been associated with greater biological aggressiveness and a higher likelihood of lymph node metastasis [130].

It is increasingly being accepted that tumor cell proliferation alone is insufficient to result in a substantial tumor mass. Angiogenesis is essential for tumors to develop into detectable localized masses, and for metastasis to occur [131, 132]. Given their central roles in tumor angiogenesis and growth, the VEGF and PDGF signaling pathways are key targets for breast cancer therapy. However, with considerable redundancy in angiogenic signaling pathways, the inhibition of more than one receptor is likely necessary to block angiogenesis. It has been hypothesized that anti-VEGF agents may prevent the development of new tumor vasculature and induce normalization of existing, inefficient tumor vasculature (resulting from overexpression of VEGF) [133]. These agents, then, may allow better delivery of cytotoxic therapies to the tumor, suggesting a potential role for anti-VEGF therapy in conjunction with chemotherapy [133, 134].

**Targeted Therapies Directed at Angiogenesis**

Several therapies targeting angiogenesis are in development for breast cancer. These include monoclonal antibodies that act extracellularly by binding to receptors or their ligands, such as bevacizumab (Avastin®; Genentech, Inc., South San Francisco, CA), and TKIs that act intracellularly, such as sunitinib (Sutent®; Pfizer, Inc., New York) (Table 1). Bevacizumab is an anti-VEGF humanized monoclonal antibody administered as an i.v. infusion. It acts by binding to all VEGF isoforms, thus removing VEGF from the circulation and preventing activation of VEGFRs [135]. Bevacizumab is currently approved for use in combination with paclitaxel as first-line treatment for patients with MBC [136].

A number of single-agent TKIs with multiple molecular targets have been developed as an alternative to combining multiple agents. These were developed based on previous studies showing that combining agents that target different pathways may have synergistic activity and delay or reverse resistance [59, 137–139]. A range of oral, antiangiogenic TKIs with multiple targets is currently in development for MBC. These include sunitinib, pazopanib, sorafenib (Nexavar®; Bayer Pharmaceuticals Corporation, West Haven,
CT), and axitinib. Sunitinib selectively inhibits several receptor tyrosine kinases (VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, Kit, REarranged during Transfection, FMS-like tyrosine kinase [FLT]-3, and colony-stimulating factor 1 receptor) [140–145]. It has antiangiogenic and antitumor activities and is approved multinationaly for the treatment of advanced renal cell carcinoma (RCC) and for gastrointestinal stromal tumors after disease progression on or intolerance to imatinib mesylate therapy [146]. Pazopanib targets VEGFR, PDGFR, and Kit and is currently in development in a number of tumor types, including breast cancer. Although originally developed as a Raf inhibitor, sorafenib also inhibits the activity of VEGF-2 and VEGF-3, PDGFR-β, FLT-3, and Kit; thus, it may inhibit tumor growth both directly (through Raf and Kit) and indirectly, through inhibition of angiogenesis [147, 148]. In both the U.S. and Europe, sorafenib is currently indicated for the treatment of patients with advanced RCC and for the treatment of unresectable hepatocellular carcinoma [149]. Axitinib inhibits all known VEGFRs, in addition to PDGFR-β and the stem cell factor receptor Kit, and is currently being investigated in a range of tumor types, including breast cancer.

**Extracellular Targeted Therapies: Monoclonal Antibodies**

**Bevacizumab.** Phase III studies have investigated bevacizumab combined with chemotherapy (Table 4) [150–153]. In 2008, the U.S. Food and Drug Administration (FDA) approved bevacizumab in combination with paclitaxel for the first-line treatment of locally recurrent breast cancer or MBC [136]. This approval was controversial after the FDA’s Oncologic Drugs Advisory Committee recommended that the phase III data (E2100) were insufficient to establish a favorable risk–benefit profile, with the efficacy data based on PFS rather than overall survival. The E2100 study reported a 52% lower risk for disease progression or death with bevacizumab in combination with paclitaxel than with paclitaxel alone and a doubling of the PFS time (paclitaxel alone, 5.8 months; combination, 11.3 months; HR, 0.48; p < .0001) [151].

Results from the phase III AVADO trial demonstrated that bevacizumab (7.5 mg/kg or 15 mg/kg once every 3 weeks) combined with docetaxel resulted in a significantly longer PFS time (the primary endpoint) than docetaxel alone (8.7 months versus 8.8 months versus 8.0 months for the low- and high-dose combination arms versus docetaxel alone) [152], although the treatment effect was not as robust as in the E2100 study. Based on the results from the AVADO trial, the existing EU label permitting the use of bevacizumab in combination with docetaxel was extended to allow bevacizumab to be combined with docetaxel, thus allowing additional patients access to bevacizumab treatment. Further analyses of the AVADO trial have revealed that treatment continuation with single-agent bevacizumab after discontinuation of docetaxel appears to delay disease progression [154], that there is no apparent correlation between the efficacy of bevacizumab plus docetaxel and hypertension or G-CSF use [155], and that the combination does not appear to be associated with a higher incidence of grade 3–5 bleeding events [156].

| Table 4. Summary of key bevacizumab trials |
|------------------------------------------|
| **Trial** | **Phase** | **Patient characteristics** | **Treatment regimen** | **Primary endpoint** | **ORR** | **PFS/TPP** | **OS** | **Safety** |
|-----------|----------|----------------------------|----------------------|---------------------|--------|-------------|--------|-----------|
| E2100     | III      | MBC, previously untreated (n = 722) | B + PX versus PX | PFS | ORR, 36.9% (B + PX) versus 21.2% (PX) (p < .001) | PFS, 11.8 mos (B + PX) versus 5.9 mos (PX) (p < .001) | OS, 26.7 mos (B + PX) versus 25.2 mos (PX) (p = .16) | Grade 3 or 4 hypertension was more frequent in B + PX arm |
| AVADO     | III      | MBC, previously untreated (n = 756) | B (low dose + high dose) + D versus D | PFS | ORR, 55% (B + D low) versus 63% (B + D high) (p = .16) | PFS, 8.7 mos (B + D low) versus 8.8 mos (B + D high) versus 8.0 mos (D) | OS, NS | No difference in grades 3–5 bleeding events |
| [150]     | III      | MBC patients with prior therapy with both an A and a T (n = 462) | B + X versus X alone | OS | ORR, 19.8% (B + X) versus 9.1% (X) (p = .001) | PFS, NS | OS, NS | Well tolerated, more grade 3 or 4 hypertension with B + X than with X |
| [153]     | III      | MBC (or locally recurrent breast cancer), previously untreated patients | B + chemotherapy (X or T or A) versus placebo + chemotherapy (X or T or A) | PFS | ORR, 35.4% (B + X) versus 23.6% (placebo + X) (p = .0097); ORR 51.9% (B + T/A) versus 37.9% (placebo + T/A) (p = .0054) | PFS, 8.6 mos (B + X) versus 5.7 mos (placebo + X) (p = .0002); PFS 9.2 mos (B + T/A) versus 8.0 mos (placebo + T/A) (p < .0001) | OS, 29.0 mos (B + X) versus 21.2 mos (placebo + X) (p = .27); OS 25.2 mos (B + T/A) versus 23.8 mos (placebo + T/A) (p = .83) | Safety consistent with prior studies. No new signals seen in either chemotherapy group |

Abbreviations: A, anthracycline; B, bevacizumab; D, docetaxel; G, grade; MBC, metastatic breast cancer; NS, not significant; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PX, paclitaxel; T, taxane; TTP, time to progression; X, capecitabine.
In summary, although bevacizumab has shown little activity as a single agent in MBC patients, combination therapy with chemotherapeutic agents has been associated with clinical activity in this patient population. This suggests that VEGF inhibition combined with chemotherapy is a promising treatment strategy in this setting. Further studies are under way to explore the use of bevacizumab with different chemotherapeutic regimens, hormonal treatments, and other targeted therapies (including lapatinib and trastuzumab) in patients with MBC. Additionally, trials of bevacizumab are ongoing in the adjuvant and neoadjuvant settings, and preliminary reports suggest that this approach may be feasible; however, there are concerns about hypertension and bleeding [157]. Indeed, hypertension, bleeding, and thrombosis remain potential safety concerns with a number of anti-VEGF therapies, and this area requires further study. Future trials should focus on identifying those patients who will derive the most benefit from bevacizumab-based regimens and how best to combine bevacizumab with other cancer therapies (which therapies should be combined and whether sequential or concurrent administration is most effective). Overall, growing clinical experience with agents targeting angiogenic processes, such as bevacizumab, has provided proof of concept for the use of these treatments in MBC patients.

**Intracellular Targeted Therapies: TKIs**

**Sunitinib.** Sunitinib has been shown to have antitumor activity in breast cancer preclinical studies, both as a single agent and in combination with chemotherapy [140, 143, 145]. Data from a phase II study of sunitinib monotherapy in patients with refractory MBC reported single-agent activity in heavily pretreated patients (n = 64), previously exposed to an anthracycline and a taxane [158]. The ORR was 11%, with a median TTP of 10 weeks, and toxicities were manageable [158]. Studies and case series evaluating sunitinib given in combination with taxane therapy for MBC have reported antitumor activity and a manageable and tolerable safety profile [159–161]. Briefly, sunitinib plus paclitaxel (n = 20) was generally well tolerated and showed preliminary evidence of clinical activity, with an ORR of 38.9% [159]. Sunitinib given sequentially with docetaxel (n = 22) also showed activity and a manageable safety profile [160, 161]. Of 18 evaluable patients in an exploratory study, 72.2% had PRs and 27.7% had SD [160]. In patients with HER-2+ MBC, sunitinib combined with trastuzumab was tolerable and associated with a preliminary ORR of 24% (n = 51) [162]. A triple combination of sunitinib, trastuzumab, and docetaxel was also found to be clinically feasible in HER-2+ MBC patients, with a preliminary ORR of 77.7% (n = 18) [163].

Phase III trials of sunitinib in combination with a variety of cytotoxic agents are under way in first- and second-line MBC therapy [164]. Although two phase III studies of sunitinib in the advanced disease setting (single-agent sunitinib in the first, second, and third lines of therapy and first-line sunitinib plus paclitaxel versus bevacizumab plus paclitaxel) have been stopped after preplanned interim analyses indicated that the primary endpoint would not be reached, other combination phase III studies are ongoing. These include SUN1099 (second- and third-line sunitinib plus capcitabine) and SUN1064 (first-line sunitinib plus docetaxel). Additionally, a phase II study is evaluating second-line sunitinib versus standard of care in previously treated advanced triple-negative breast cancer (SUN 1077) [104].

**Pazopanib.** Results of a phase II study (VEG20007) evaluating combination therapy with pazopanib and lapatinib versus lapatinib alone described superior activity with the combination of the two small molecule TKIs, pazopanib plus lapatinib versus lapatinib alone, in HER-2+ patients (n = 140) (Table 3) [82]. At the interim analysis, the response rate (independent assessment) was higher for the combination (36%; n = 32) than for lapatinib monotherapy (22%; n = 30), whereas there was no significant difference in the rate of progressive disease [82]. This is the first phase II trial to demonstrate the clinical activity of TKIs (in the absence of chemotherapy) in the first-line treatment of MBC patients. However, because of the small sample size, heterogeneous population, and some missing efficacy data (15%–20% of patients in both groups), these can be considered preliminary data only.

**Sorafenib.** Sorafenib inhibited MAPK activity in breast cancer cell lines expressing mutations of K-Ras or B-Raf, and showed antitumor and antiangiogenic activity in a human breast cancer xenograft model [148]. Data from a phase II study in patients with MBC (n = 23) previously exposed to an anthracycline and/or a taxane showed no significant clinical activity with sorafenib (6-month OS rate, 81%; 2-month PFS rate, 53%; 4-month PFS rate, 24%; 6-month PFS rate, 6%) [165]. Single-agent treatment was well tolerated in that study; however, significant and sustained increases in blood pressure were reported in a study of sorafenib monotherapy in patients with metastatic solid tumors [165, 166]. Current data suggest little activity for sorafenib as a single agent in MBC patients; ongoing studies are exploring combination treatment with paclitaxel and with anastrozole in MBC.

**Axitinib.** In preclinical studies, axitinib was shown to selectively block VEGF-stimulated receptor phosphorylation
in vitro, resulting in the inhibition of endothelial cell proliferation and survival, and in a human breast cancer xenograft model it significantly inhibited tumor growth and disrupted tumor microvasculature as assessed by dynamic contrast-enhanced magnetic resonance imaging [167]. A randomized, double-blind phase II study of axitinib in combination with docetaxel versus docetaxel as first-line therapy for patients with MBC \((n = 168)\) has shown that this regimen has promising antitumor activity [168]. In the overall patient population \((n = 168)\), the TTP was 8.2 months for patients in the combination arm versus 7 months for patients treated with docetaxel alone \((p = .052)\) and the ORR was 40% for patients in the combination arm versus 23% for those given docetaxel alone \((p = .038)\). In a prior adjuvant chemotherapy subgroup \((n = 92)\), the TTP was 9.0 months for axitinib plus docetaxel versus 6.3 months for docetaxel alone \((p = .012)\) and the ORR was 45% for axitinib plus docetaxel versus 13% for docetaxel alone \((p = .003)\) [168]. The treatment had an acceptable safety profile that was similar to that of other multitargeted agents [168].

Table 5. Key trials of antiangiogenic TKIs in MBC patients, recruiting as of June 2009

| Drug     | Trial identifier | Phase | Patient characteristics | Expected \(n\) of patients enrolled | Treatment regimen | Line of therapy | Primary endpoint |
|----------|-----------------|-------|-------------------------|-----------------------------------|------------------|----------------|-----------------|
| Sunitinib | NCT00435409     | III   | ABC                     | 430                               | SU + X versus X | Second line    | PFS             |
|          | (SUN 1099)      |       |                         |                                   |                  |                |                 |
|          | NCT00393939     | III   | ABC                     | 550                               | SU + D versus D | First line     | PFS             |
|          | (SUN 1064)      |       |                         |                                   |                  |                |                 |
|          | NCT00246571     | II    | ABC triple negative     | 200                               | SU versus standard of care chemotherapy | Second line    | PFS             |
|          | (SUN 1077)      |       |                         |                                   |                  |                |                 |
| Pazopanib | NCT00509587     | II    | MBC                     | 35                                | PZ versus PL     | Second line    | ORR             |
| Sorafenib | NCT00632541     | II    | MBC                     | 43                                | SB + B           | Second line    | PFS             |
|          | NCT00499525     | II    | MBC                     | 180                               | SB + PX versus PX | First line    | PFS             |
|          | NCT00622466     | II    | MBC                     | 41                                | SB + PX          | First line     | ORR             |
|          | NCT00217399     | I/II  | MBC triple negative     | 50                                | SB + A           | Second line    | CBR             |
|          | NCT00722072     | II    | MBC triple negative     | 43                                | SB + F           | Second line    | PFS             |
|          | NCT00493636     | II    | MBC triple negative     | 220                               | SB versus PL     | First or Second line | PFS         |

Abbreviations: A, anastrozole; ABC, advanced breast cancer; B, bevacizumab; CBR, clinical benefit rate; D, docetaxel; DR, duration of response; F, fulvestrant; MBC, metastatic breast cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PL, placebo; PX, paclitaxel; PZ, pazopanib; SB, sorafenib; SU, sunitinib; TKI, tyrosine kinase inhibitor; Triple negative, estrogen receptor negative, progesterone receptor negative, and human epidermal growth factor receptor 2 negative; X, capecitabine.

Table 5. Key trials of antiangiogenic TKIs in MBC patients, recruiting as of June 2009

CONCLUSIONS

In recent years, research efforts have focused on the signaling pathways involved in the growth and survival of breast cancer cells, leading to the development of a range of targeted agents with promising clinical activity. The encouraging success of trastuzumab, based on the identification of HER-2 as a molecular target, has provided the rationale for studying the array of targeted agents currently in clinical development for MBC. The various extracellular and intracellular targets of breast cancer therapies discussed in this review are presented in Fig. 3.

The lapatinib data have shown that other means of HER family targeting are effective, although the lack of success with erlotinib and gefitinib underlines the importance of careful evaluation of these agents. Ongoing research must define how and when to use trastuzumab and lapatinib in the various treatment lines for MBC. Numerous therapies that target intracellular signaling molecules are in development, and early evidence suggests that some of these agents (everolimus and tanespimycin) may have clinical utility in...
MBC patients. Antiangiogenic drugs have also shown clinical benefit in this patient population, with the anti-VEGF antibody bevacizumab already licensed in combination with chemotherapy. Therapies targeting multiple receptors, including sunitinib and pazopanib, are also demonstrating clinical activity in early trials. It is anticipated that combining these treatments with other targeted agents and/or chemotherapy may offer an effective approach to the future treatment of MBC patients, but combinations of the targeted agents must be evaluated carefully for acceptable toxicity profiles.

Future studies will need to address how best to incorporate these agents into existing treatment regimens, to identify those patient subgroups likely to derive most benefit from a given therapy, and to determine when and in which combinations targeted therapy should be administered.

ACKNOWLEDGMENTS
Medical writing support was provided by Helen Louise Ashurst at ACUMED® (Tytherington, U.K.) and funded by Pfizer Inc.

AUTHOR CONTRIBUTIONS
Conception/Design: Linnea Chap, Lee Rosen
Administrative support: Helen Louise Ashurst
Manuscript writing: Linnea Chap, Helen Louise Ashurst, Lee Rosen
Final approval of manuscript: Linnea Chap, Helen Louise Ashurst, Lee Rosen

REFERENCES
1. Gasparini G, Longo R, Torino F et al. Therapy of breast cancer with molecular targeting agents. Ann Oncol 2005;16(suppl 4):iv28–iv36.
2. Buchholz TA, Wazer DE. Molecular biology and genetics of breast cancer development: A clinical perspective. Semin Radiat Oncol 2002;12:285–295.
3. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000;406:747–752.
4. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003;100:10393–10398.
5. Paik S. Molecular profiling of breast cancer. Curr Opin Obstet Gynecol 2006;18:59–63.
6. Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004;319:1–11.
7 Stern DF. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res 2000;2:176–183.

8 Martin M. Molecular biology of breast cancer. Clin Transl Oncol 2006;8:7–14.

9 Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–182.

10 Ménard S, Fortis S, Castiglioni F et al. HER2 as a prognostic factor in breast cancer. Oncology 2001;61(suppl 2):67–72.

11 Bender LM, Nahta R. Her2 cross talk and therapeutic resistance in breast cancer. Front Biosci 2008;13:3906–3912.

12 Milanesi F, Carvalho S, Schmitt FC. EGFR/HER2 in breast cancer: A biological approach for molecular diagnosis and therapy. Expert Rev Mol Diagn 2008;8:417–434.

13 Lin NU, Winer EP. New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors. Breast Cancer Res Treat 2004;6:204–210.

14 Riese DJ 2nd, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998;20:41–48.

15 Mills GB, Lu Y, Fang X et al. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 2001;28(suppl 16):125–141.

16 Salomon DS, Brandt R, Ciardiello F et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183–232.

17 Tsutsui S, Ohno S, Murakami S et al. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 2002;71:67–75.

18 Vogt U, Bielawski K, Schlötter CM et al. Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer. Gene 1998;223:375–380.

19 Witton CJ, Reeves JR, Going JJ et al. Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003;200:290–297.

20 Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707–712.

21 Pawlowski V, Révillion F, Hebbar M et al. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2001;6:4217–4225.

22 Barrett-Lee PJ. Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: A review of chemotherapy. Endocr Relat Cancer 2005;12(suppl 1):S125–S135.

23 Normanno N, Di Maio M, De Maio E et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005;12:721–747.

24 Atalay G, Cardoso F, Awada A et al. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol 2003;14:1346–1363.

25 Graus-Porta D, Beerli RR, Daly JM et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647–1655.

26 Prenzel N, Fischer OM, Streit S et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001;8:11–31.

27 Cho HS, Mason K, Ramyar KX et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756–760.

28 Gelmon KA, Fumoleau P, Verma S et al. Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy [abstract 1026]. J Clin Oncol 2008;26(15 suppl):47s.

29 Data on file. New York: Pfizer Inc., 2007.

30 Nemunaitis J, Eisenai I, Cunningham C et al. Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res 2005;11:3846–3853.

31 Herceptin® (trastuzumab) [full prescribing information]. South San Francisco, CA: Genentech, Inc., 2009.

32 Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–2648.

33 Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–792.

34 Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005;23:4265–4274.

35 Bontenbal M, Seynaeve C, Stouthard J et al. Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first-line chemotherapy in HER2-neu positive, metastatic breast cancer (MBC) (HERTAX study) [abstract 1014]. J Clin Oncol 2008;26(15 suppl):44s.

36 Seidman AD, Conlin AK, Bach AM et al. Phase II study of weekly nanoparticle albumin bound (nab)paclitaxel with carboplatin and trastuzumab as 1st-line therapy for HER2-positive metastatic breast cancer (MBC) [abstract 1047]. J Clin Oncol 2008;26(15 suppl):S2s.

37 Chia S, Clemons M, Martin LA et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicenter phase II trial. J Clin Oncol 2006;24:2773–2778.

38 Burstein HJ, Keshaviah A, Baron AD et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study. Cancer 2007;110:965–972.

39 Robert N, Leyland-Jones B, Asmar L et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer. J Clin Oncol 2006;24:2786–2792.

40 Pegram M, Forbes J, Pienkowski T et al. BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC) [abstract LBA1008]. J Clin Oncol 2007;25(suppl 18):34s.

41 Inoue K, Nakagami K, Mizutani M et al. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: The JO17360 Trial Group. Breast Cancer Res Treat 2010;119:127–136.

42 Wardley A, Anton-Torres A, Pivot X et al. Evaluation of trastuzumab, docetaxel and capcitabine as first-line therapy for HER2-positive locally
advanced or metastatic breast cancer. Breast Cancer Res Treat 2007;106(suppl 1):309.

von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03–05 study. J Clin Oncol 2009;27:1999–2006.

Modi S, Sugarman S, Stopec A et al. Phase II trial of the Hsp90 inhibitor tanespimycin (Tans) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) [abstract 1027]. J Clin Oncol 2008;26(15 suppl):47s.

Baselga J, Imadlou K, Paton V et al. Efficacy, safety and tolerability of dual monoclonal antibody therapy with pertuzumab + trastuzumab in HER2+ metastatic breast cancer patients previously treated with trastuzumab. Cancer Res 2009;69(2 suppl):3138.

O’Regan R, Andre F, Campone M et al. RAD001 (everolimus) in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpression metastatic breast cancer with prior resistance to trastuzumab: A multicenter phase I clinical trial. Cancer Res 2009;69(2 suppl):3119.

Fasolo A, Gianni L, Rorive A et al. Multicenter phase I clinical trial of lapatinib and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. Cancer Res 2009;69(2 suppl):406.

Wong Y, Ottesen R, Niland J et al. Continued use of trastuzumab (TRZ) beyond disease progression in the National Comprehensive Cancer Network (NCCN) [abstract 6522]. J Clin Oncol 2008;26(15 suppl):342s.

Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5559–5577.

Marcom PK, Isaacs C, Harris L et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007;102:43–49.

Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719–726.

Burris H 3rd, Yardley D, Jones S et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 2004;22:1621–1629.

Sawaki M, Ito Y, Tada K et al. Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer. Tumor 2004;90:40–43.

Nahta R, Yu D, Hung MC et al. Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3:269–280.

Gelmon KA, Mackey J, Verma S et al. Use of trastuzumab beyond disease progression: Observations from a retrospective review of case histories. Clin Breast Cancer 2004;5:52–58; discussion 59–62.

Bartsch R, Wenzel C, Hussan D et al. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study. BMC Cancer 2006;6:63.

Bachelot T, Mauriac L, Delcambre C et al. Efficacy and safety of trastuzumab plus vinorelbine as second-line treatment for women with HER2-positive metastatic breast cancer beyond disease progression [abstract 1094]. J Clin Oncol 2007;25(18 suppl):55s.
Spielmann M, Roché H, Delozier T et al. Trastuzumab for patients with axillary-node-positive breast cancer: Results of the FNCLCC-PACS-04 Trial. J Clin Oncol 2009;27:6129–6134.

Untch M, Rezai M, Loibl S et al. Evaluating the efficacy and safety of trastuzumab given concomitantly to epirubicin/cyclophosphamide – docetaxel +/- capcitabine as neoadjuvant treatment of HER2 overexpressing primary breast cancer. First analysis of the GBG/AGO intergroup study “GeparQuattro”. Br Cancer Res Treat 2007;106:S224.

GlaxoSmithKline Receives Marketing Authorisation in the EU for Tykerb® (lapatinib), the First Oral Targeted Therapy for ErbB2-Positive Breast Cancer [press release]. Philadelphia, PA: GlaxoSmithKline, June 21, 2008.

Tykerb® (lapatinib) Tablets [prescribing information]. Philadelphia, PA: GlaxoSmithKline, 2007.

Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733–2743.

Ruco HS, Franco S, Munster P et al. A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+ metastatic breast cancer (MBC) [abstract 1042]. J Clin Oncol 2008;26(15 suppl):51s.

Slamon D, Gomez HL, Kabbabnavar FF et al. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer [abstract 1016]. J Clin Oncol 2008;26(15 suppl):45s.

Slamon DJ, Stemm SM, Johnston S et al. Phase 2 study of dual VEGF/HER2 blockade with pazopanib + lapatinib in patients with first-line HER2 positive advanced or metastatic (adv/met) breast cancer. Cancer Res 2009;69(2 suppl):4114.

Dickler M, Franco S, Stopeck A et al. Final results from a phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2-overexpressing metastatic breast cancer (MBC). Cancer Res 2009;69(2 suppl):3133.

Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008;26:1993–1999.

Boccadillo F, Kaufman B, Baselga J et al. Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d’Utilisation (ATU) [abstract 1094]. J Clin Oncol 2008;26(15 suppl):64s.

Lin NU, Diéras V, Paul D et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009;15:1452–1459.

Perez EA, Koehler M, Byrne J et al. Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008;83:679–686.

De Placido S, Link J, Conte PF et al. Lapatinib Expanded Access Program (LEAP): Design, operation and initial safety data. Breast Cancer Res Treat 2007;106:S273.

Koehler M, Chan S, Newstall BO et al. Diarrhea events in cancer patients (pts) treated with lapatinib [abstract 9125]. J Clin Oncol 2007;25(18 suppl):523s.

OSI Pharmaceuticals, Genentech and Roche announce data from clinical studies of Tarceva. Expert Rev Anticancer Ther 2001;1:4–5.

Cohen MH, Williams GA, Sridhara R et al. United States Food and Drug Administration drug approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212–1218.

Green MD, Francis PA, Gelski V et al. Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Ann Oncol 2009;20:1813–1817.

von Minckwitz G, Jonat W, Fasching P et al. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 2005;93:165–172.

Ciardiello F, Trotani C, Caputo F et al. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer 2006;94:1604–1609.

Dennison SK, Jacobs SA, Wilson JW et al. A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. Invest New Drugs 2007;25:545–551.

Arteaga CL, O’Neill A, Moulder SL et al. A phase I–II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin Cancer Res 2008;14:6277–6283.

Dickler MN, Cobleigh MA, Miller KD et al. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2009;115:115–121.

Britten CD, Finn RS, Bosserman LD et al. A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: A dual ErbB targeted approach. Clin Breast Cancer 2009;9:16–22.

Bose P, Ozer H, Neratinib. An oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert Opin Invest Drugs 2009;18:1735–1751.

Wong KK, Fracasso PM, Bukowski RM et al. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res 2009;15:2552–2558.

Chow L, Jiang J, Epstein R et al. Safety and efficacy of neratinib (HKI-272) in combination with paclitaxel in patients with solid tumors. J Clin Oncol 2009;27(15 suppl):3557.

Swaby R, Blackwell K, Jiang Z et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: A phase I/II study. J Clin Oncol 2009;27(15 suppl):1004.

ClinicalTrials.gov. Available at http://www.clinicaltrials.gov, accessed December 1, 2009.

Kolch W. Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000;351:289–305.

Sparano JA, Moulder S, Kazi A et al. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: A phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. J Clin Oncol 2006;24:3013–3018.

Johnston SR, Semiglazov VF, Manikhas GM et al. A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res Treat 2008;110:327–335.

Kondapaka SB, Singh SS, Dasanapatha GP et al. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003;2:1093–1103.

Johnston SR, Hickish T, Ellis P et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 2003;21:2492–2499.

Johnston SR, Semiglazov VF, Manikhas GM et al. A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res Treat 2008;110:327–335.

Kondapaka SB, Singh SS, Dasanapatha GP et al. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003;2:1093–1103.

Chen S, Scheulen ME, Johnston S et al. Phase II study of temsirolimus (CC1-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005;23:5314–5322.

Hahn OM, Ma CX, Lin L et al. A phase II trial of a mammalian target of
rapamycin inhibitor, temsirolimus, in patients with metastatic breast cancer. Cancer Res 2009;69(2 suppl):407.

112 Baselga J, Roche H, Fumoleau P et al. Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: A randomized, 3-arm, phase 2 study. Breast Cancer Res Treat 2005;94(suppl 1):1068.

113 Jerusalem GH, Diers V, Cardoso F et al. Multicenter phase I clinical trial of daily and weekly RAD001 in combination with vinorelbine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab [abstract 1057]. J Clin Oncol 2008; 26(15 suppl):55s.

114 André F, Camponge M, Harwitz H et al. Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab [abstract 1003]. J Clin Oncol 2008;26(15 suppl):41s.

115 Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000;21:485–495.

116 Reed JC. Dysregulation of apoptosis in cancer. Cancer Cell 2003;3:17–22.

117 Reed JC. Apoptosis-targeted therapies for cancer. Cancer Cell 2003;3:17–22.

118 Nahta R, Esteva FJ. Bcl-2 antisense oligonucleotides: A potential novel strategy for the treatment of breast cancer. Semin Oncol 2003;30(suppl 16):143–149.

119 Sjöström J, Blomqvist C, von Boguslawski K et al. The predictive value of Bcl-2, Bax, Bcl-xL, Bag-1, Fas, and FasL for chemotherapy response in advanced breast cancer. Clin Cancer Res 2002;8:811–816.

120 Krajewska S, Krajewska M, Turner BC et al. Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer 1999;6:29–40.

121 McCarthy MM, Sznoi M, DiVito KA et al. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res 2005;11:5188–5194.

122 Citri A, Kochupurakkal BS, Yarden Y. The Achilles heel of ErbB2/HER2: Regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 2004;3:51–60.

123 Citri A, Gan J, Mosesson Y et al. Hsp90 restrains ErbB2/HER2 signalling by limiting heterodimer formation. EMBO Rep 2004;5:1165–1170.

124 Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011–1027.

125 Board R, Jayson GC. Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics. Drug Resist Updat 2005;8:75–83.

126 Relf M, LeJeune S, Scott PA et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotropin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963–969.

127 Gasparini G, Toi M, Gion M et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997;89:139–147.

128 Gasparini G, Toi M, Miceli R et al. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Cancer J Sci Am 1999;5:101–111.

129 Foekens JA, Peters HA, Grebenschchikov N et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001;61:5407–5414.

130 Carvalho I, Milanezi F, Martins A et al. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res 2005;7:R788–R795.

131 Folkman J. Angiogenesis. Annu Rev Med 2006;57:1–18.

132 Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29(suppl 16):15–18.

133 Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005;307:58–62.

134 Rosen LS. VEGF-targeted therapy: Therapeutic potential and recent advances. The Oncologist 2005;10:382–391.

135 Presta LG, Chen H, O’Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593–4599.

136 FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer [press release]. South San Francisco, CA: Genentech, February 22, 2008.

137 Carraway H, Hidalgo M. New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 2004; 6:219–224.

138 Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630–1639.

139 Chu I, Blackwell K, Chen S et al. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res 2005;65:18–25.

140 Murray LJ, Abrams TJ, Long KR et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003;20:757–766.

141 Sapi E. The role of CSF-1 in normal physiology of mammary gland and breast cancer: An update. Exp Biol Med (Maywood) 2004;229:1–11.

142 Abrams TJ, Lee LB, Murray LJ et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471–478.

143 Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327–337.

144 O’Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597–3605.

145 Abrams TJ, Lee LB, Murray LJ et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:1011–1027.

146 Wilhelm SM, Carter C, Tang L et al. BAY 43–9006 exhibits broad specificity and angiogenesis pathways. Cancer Res 2009;69(2 suppl):407.

147 O’Farrell AM, Abrams TJ, Yuen HA et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597–3605.

148 Adams L, Trail PA, Taylor I et al. Sorafenib (BAY 43–9006, Nexavar®), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 2006;407:597–612.
receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099–7109.

149 Nexavar® (sorafenib) [prescribing information]. West Haven, CT: Bayer Pharmaceuticals Corporation, 2007.

150 Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capcitabine compared with bevacizumab plus capcitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792–799.

151 Miller K, Wang M, Grawal J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666–2676.

152 Miles D, Chan A, Romieu G et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO [abstract LBA101]. J Clin Oncol 2008;26(15 suppl):43s.

153 Robert NJ, Diersas V, Glasy P et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer [abstract 1005]. J Clin Oncol 2009;27(15 suppl):42s.

154 Finoleau P, Greil R, Rayson D et al. Bevacizumab (BV) maintenance therapy significantly delays disease progression (PD) or death compared with placebo (PL) in the AVADO trial (BV + docetaxel [D] vs D + PL in 1st-line HER2-negative locally recurrent [LR] or metastatic breast cancer [mBC]). Cancer Res 2009;69(2 suppl):903.

155 Chan A, Vanlemmens L, Conte PF et al. Efficacy of bevacizumab (BV) plus docetaxel (D) does not correlate with hypertension (HTN) or G-CSF use in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) in the AVADO phase III study. Cancer Res 2009;69(2 suppl):1027.

156 Cortés J, Pivot X, Schneeweiss A et al. Safety of surgery in patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC) treated with docetaxel (D) plus bevacizumab (BV) or placebo (PL) in the AVADO phase III study. Cancer Res 2009;69(2 suppl):1030.

157 Miller KD, O’Neill A, Perez EA et al. Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: A trial of the Eastern Cooperative Oncology Group (E2104) [abstract 520]. J Clin Oncol 2008;26(15 suppl):11s.

158 Burstein HI, Elias AD, Rugo HS et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008;26:1810–1816.

159 Kozloff M, Chuang E, Starr A et al. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol 2009 Dec 23 [Epub ahead of print].

160 Mariani G, Cardoso F, Besse-Hamme T et al. Sequential administration of sunitinib (SU) and docetaxel (D) in women with advanced breast cancer (ABC): An exploratory evaluation [abstract 14534]. J Clin Oncol 2008;26(15 suppl):630s.

161 Liljegren A, Bergh J, Castany R. Early experience with sunitinib, combined with docetaxel, in patients with metastatic breast cancer. Breast 2009;18:259–262.

162 Blay JY, Lluch A, Gutierrez M et al. Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: Activity and safety results from a phase II study. Cancer Res 2010;70:201.

163 Dirix L, Canon JL, Amadori D et al. An exploratory study of sunitinib plus docetaxel plus trastuzumab for first-line therapy of HER2+ advanced breast cancer. Cancer Res 2010;70:6088.

164 The Sun Program. SUN Breast Cancer Clinical Trials. Available at https://www.suntrials.com/breast_cancer_trials.aspx, accessed February 19, 2010.

165 Moreno-Aspitia A, Hillman DW, Wiesenfeld M et al. BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane [abstract 577]. J Clin Oncol 2006;24(18 suppl):22s.

166 Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43–9006. J Clin Oncol 2006;24:1363–1369.

167 Wilmes LJ, Pallavicini MG, Fleming LM et al. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases tumor permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging 2007;25:319–327.

168 Rugo HS, Stopeck A, Joy AA et al. A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC) [abstract 1003]. J Clin Oncol 2007;25(18 suppl):32s.